Skip to Main Content

After three years of probing, the European Commission has reached a preliminary decision that Teva Pharmaceuticals illegally used different strategies to prevent rival companies from introducing versions of a top-selling medicine.

The review found that Teva used various patent maneuvers to thwart generic manufacturers from being able to market copycat versions of the Copaxone multiple sclerosis treatment. The European Commission also determined that the company ran a campaign directed at hospitals and doctors to create “false perceptions” of similar multiple sclerosis medicines.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment